Ogeda
Brussels
About Ogeda
Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $30.9M
- Funding stage: M&A
- Last round: Series B (Oct 2015)
- Website: ogeda.com
- Phone: (327)134-8500
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ogeda-2761517 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.